Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency.
J Allergy Clin Immunol Pract
; 7(3): 848-855, 2019 03.
Article
en En
| MEDLINE
| ID: mdl-30391550
ABSTRACT
BACKGROUND:
Biallelic variations in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined immunodeficiency with eczema, recurrent bacterial and viral infections, and malignancy. Natural disease outcome is dismal, but allogeneic hematopoietic stem cell transplantation (HSCT) can cure the disease.OBJECTIVE:
To determine outcome of HSCT for DOCK8 deficiency and define possible outcome variables.METHODS:
We performed a retrospective study of the results of HSCT in a large international cohort of DOCK8-deficient patients.RESULTS:
We identified 81 patients from 22 centers transplanted at a median age of 9.7 years (range, 0.7-27.2 years) between 1995 and 2015. After median follow-up of 26 months (range, 3-135 months), 68 (84%) patients are alive. Severe acute (III-IV) or chronic graft versus host disease occurred in 11% and 10%, respectively. Causes of death were infections (n = 5), graft versus host disease (5), multiorgan failure (2), and preexistent lymphoma (1). Survival after matched related (n = 40) or unrelated (35) HSCT was 89% and 81%, respectively. Reduced-toxicity conditioning based on either treosulfan or reduced-dose busulfan resulted in superior survival compared with fully myeloablative busulfan-based regimens (97% vs 78%; P = .049). Ninety-six percent of patients younger than 8 years at HSCT survived, compared with 78% of those 8 years and older (P = .06). Of the 73 patients with chimerism data available, 65 (89%) had more than 90% donor T-cell chimerism at last follow-up. Not all disease manifestations responded equally well to HSCT eczema, infections, and mollusca resolved quicker than food allergies or failure to thrive.CONCLUSIONS:
HSCT is curative in most DOCK8-deficient patients, confirming this approach as the treatment of choice. HSCT using a reduced-toxicity regimen may offer the best chance for survival.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Factores de Intercambio de Guanina Nucleótido
/
Síndromes de Inmunodeficiencia
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
J Allergy Clin Immunol Pract
Año:
2019
Tipo del documento:
Article
País de afiliación:
Alemania